Asleson Louise, Zalabani Mohammed, Selim Mohammad
Internal Medicine, Creighton University School of Medicine, Omaha, USA.
Cureus. 2022 Sep 23;14(9):e29491. doi: 10.7759/cureus.29491. eCollection 2022 Sep.
Renal vein thrombosis (RVT) is a rare form of deep venous thrombosis. It usually involves one or both renal veins and one of their branches. Most cases were reported in patients with nephrotic syndrome or inherited hypercoagulability syndromes. RVT can present with flank pain, hematuria, and acute kidney injury but can also present asymptomatically and be incidentally discovered on abdominal or renal imaging. The management of RVT is usually with warfarin for at least six to 12 months and periodically is continued if the patient is in the nephrotic range. Direct-acting oral anticoagulants (DOACs) have not been well studied in cases of RVT, especially in patients with coronavirus disease 2019 (COVID-19). We present a case of RVT in the setting of COVID-19 that was treated successfully with a DOAC, rivaroxaban, with complete resolution of the thrombus.
肾静脉血栓形成（RVT）是一种罕见的深静脉血栓形成形式。它通常累及一条或两条肾静脉及其分支之一。大多数病例报告于肾病综合征或遗传性高凝综合征患者。RVT可表现为胁腹痛、血尿和急性肾损伤，但也可能无症状，并在腹部或肾脏影像学检查时偶然发现。RVT的治疗通常使用华法林至少6至12个月，如果患者处于肾病范围，则需定期持续使用。直接口服抗凝剂（DOACs）在RVT病例中尚未得到充分研究，尤其是在2019冠状病毒病（COVID-19）患者中。我们报告一例在COVID-19背景下发生的RVT病例，该病例用DOAC利伐沙班成功治疗，血栓完全溶解。
